The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Aktis’ IPO ranks as the industry’s third-largest since the start of 2024, only trailing offerings from Kyverna Therapeutics and CG Oncology.

    Updated 12 hours ago
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal

    Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

  • A man dressed in a suit looks at the camera in this headshot.
    Image attribution tooltip
    Permission granted by FogPharma
    Image attribution tooltip
    Emerging biotech

    Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz

    The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the top of 2026.

  • A headshot of Alex Lugovskoy.
    Image attribution tooltip
    Permission granted by Diagonal Therapeutics
    Image attribution tooltip
    Emerging biotech

    Diagonal banks another $125M for ‘clustering’ antibody drugs

    Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of treating two disparate conditions, one of which is the target of Merck’s fast-selling Winrevair. 

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Biotechs backed by the venture firms BioPharma Dive tracks have raised nearly $700 million this week, an early surge that adds to a months-long rise in startup funding.

    Updated Jan. 8, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK, Ionis claim study success for RNA-based hepatitis B drug

    The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

  • Autophagy is a process where cells degrade and recycle their own components. Damaged or unnecessary cellular material is enclosed in a membrane, forming an autophagosome, which then fuses with a lysosome.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    EpiBiologics raises $107M for its protein-degrading cancer drug

    The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of several marketed therapies.

  • U.S. President Donald Trump, accompanied by Food and Drug Administration Commissioner Marty Makary (L), National Institutes of Health Director Jayanta Bhattacharya (2nd-L), Health and Human Services Secretary Robert F. Kennedy Jr. (2nd-R) and Domestic Policy Council Director Vince Haley (R), signs an executive order in the Oval Office at the White House on May 05, 2025 in Washington, DC
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Vaccines

    CDC, following Trump’s orders, weakens US stance on childhood vaccinations

    In a drastic decision made outside of its typical review process, the agency declared it would recommend 11 childhood shots going forward, down from 17.

    Updated Jan. 6, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug

    Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got less crowded and Amgen and Lilly struck startup deals.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

    Eli Lilly is paying $14 per share, or about $1.2 billion, to acquire Ventyx Biosciences and oral drugs it’s been developing for immune diseases.

    Updated Jan. 7, 2026
  • African American Woman With Itchy Skin. Allergy Or Psoriasis
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Alumis soars as TYK2 drug hits mark in psoriasis trials

    Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.

  • The exterior of Amgen's office building in South San Francisco, with a sculpted company sign in the foreground and leafless trees on a grassy lawn.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Emerging biotech

    Amgen buys protein-degrading startup Dark Blue for up to $840M

    The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that could set it apart from current medications. 

  • Wall street sign in New York City with New York Stock Exchange background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Zenas shares crash after top drug misses expectations in immune disease study

    While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Roche on Friday inked its second recent deal with Medilink, while startup Airnexis Therapeutics debuted with a dual-acting lung disease drug licensed from Haisco Pharmaceutical.

    Updated 5 hours ago
  • Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Vaccines

    Moderna, searching for a rebound, to seek approval of mRNA flu shot

    The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo launches Wegovy pill; Argenx to swap CEOs

    Novo Nordisk officially began marketing the pill version of its popular weight loss drug. Elsewhere, Sanofi bought a vaccine maker and an eczema therapy J&J acquired in a billion-dollar deal failed a key test. 

  • A photo of President Trump at the White House in front of several pharmaceutical executives
    Image attribution tooltip
    Alex Wong / Staff via Getty Images
    Image attribution tooltip
    Trump administration

    Biopharma climbs higher as 9 drugmakers ink ‘pandering’ drug price deals with Trump

    Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive other benefits from the agreements.

  • Thumbs down
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biopharma CEO optimism is wavering in the US

    The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo Nordisk’s weight loss pill approved by FDA

    The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market. 

  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences in 2026

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

  • 3D render using close-up of heart model covered with white, red, yellow pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Cytokinetics set to battle Bristol Myers as FDA approves heart drug

    The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which is on its way to topping $1 billion in sales this year.

  • A periodic table of the elements centered on the element actinium is partially blurred.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Radiopharmaceutical specialist Aktis seeks an IPO

    The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.

  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

    Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could broaden its use in obesity. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug

    Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise.

  • Businessmen handshake at meeting.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin to buy rare disease drugmaker Amicus for $4.8B

    Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies that generated nearly $450 million over the first nine months of this year.